KP-1077 is under clinical development by Zevra Therapeutics and currently in Phase II for Idiopathic Hypersomnia (IH). According to GlobalData, Phase II drugs for Idiopathic Hypersomnia (IH) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the KP-1077 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

KP-1077 overview

KP-1077 is under development for the treatment of idiopathic hypersomnia (IH) and narcolepsy type I and II. The drug candidate is a prodrug of serdexmethylphenidate (SDX), developed based on ligand-activated therapy (LAT) platform. It is administered through oral route.

Zevra Therapeutics overview

Zevra Therapeutics (Zevra) formerly KemPharm Inc, s a rare disease therapeutics company that offers discovery and development of proprietary new molecular entity prodrugs. Its product portfolio include Arimoclomol, KP1077IH, KP1077N and Azstarys. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company’s lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company’s prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older. Zevra is headquartered in Florida, the US.

For a complete picture of KP-1077’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.